Hyloris Pharmaceuticals Sa · EURONEXT:HYL
Hyloris Pharmaceuticals Sa — H1 2021 Earnings Presentation
16 slides from Hyloris Pharmaceuticals Sa's earnings presentation, Aug 4, 2021
Slide 1: 2021 Half-Year Results
Reformulating the Future 2021 Half-Year Results 4 August 2021
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation has been prepared by, and is the sole responsibility of, Hyloris Pharmaceuticals SA (the "Company") for discussions with investors in relation to the Company and its group. For the purposes of this notice, “presentation” means this document, oral presenta
Slide 3: Agenda for Today's Call
Agenda for Today’s Call • Hyloris: geared for growth • Business update year-to-date • Financial results first half 2021 • Outlook for the remainder of the year • Q&A \2
Slide 4: Rethinking, Reinventing, Optimising Existing Medications
Rethinking, Reinventing, Optimising Existing Medications To improve overall therapy outcomes REFORMULATING Changing dose or route of administration REPURPOSING/ Finding new indications REPOSITIONING For the benefit of patients, physicians, payors 3
Slide 5: Faster Innovation at Considerably Lower Costs and Risks
Faster Innovation at Considerably Lower Costs and Risks Discovery, pre- Regulatory clinical Clinical Development submission & development decision 15 YEARS ON AVERAGE “Traditional Pharma-Biotech Model” $1.3 BILLION COSTS ON AVERAGE Feasibility, Regulatory Clinical formulation, submission & Developme
Slide 6: Potential Game Changer, Geared for Growth
Potential Game Changer, Geared for Growth MULTIPLE SHOTS ON GOAL COMMERCIAL PORTFOLIO ≤ 7 years to market 2 patented products with partners ≤ €7 million average cost to market Addressing unmet needs Lower risk as we start from existing drugs Build U.S. commercial team Innovative, patented, value- Re
Slide 7: Broad, Innovative Portfolio: Expand to ~30 Assets by 2024
Broad, Innovative Portfolio: Expand to ~30 Assets by 2024 Formulation and Clinical Regulatory Expected Product RoA Indication Manufacturing Development Filing Launch CARDIOVASCULAR (CV) PORTFOLIO Maximum 7 years Sotalol IV IV Atrial fibrillation Launched in U.S./partnered with AltaThera ’201 Dofetil
Slide 8: Maxigesic IV: Significant Growth of Commercial Footprint
Maxigesic IV: Significant Growth of Commercial Footprint Germany & Austria: launched + strong local distribution partners Nordics: licensed Ireland, U.K., The Netherlands: licensed Eastern Europe: licensed 4 August 31 March U.S.: licensed Korea: Countries Spain, Portugal, France: Greece: licensed 20
Slide 9: Sotalol IV: Expanded Sales Force to Foster Growth
Sotalol IV: Expanded Sales Force to Foster Growth • Expansion of AltaThera’s sales force to accelerate roll-out in the U.S. Fast onset, particularly crucial in acute AF settings Hospital stay monitoring significantly reduced $ Significant potential cost reduction Oral sotalol initiation AF increment
Slide 10: Unique Partnership with Purna Female Health (PFH)
Unique Partnership with Purna Female Health (PFH) To address unmet needs in severe and recurring VVC • Infection caused by Candida sp. yeast • 10% of all women globally Pain, • No effective treatments due to drug-resistant biofilm of yeast depression, shame, • $14.4 Bn annual estimated economic burd
Slide 11: Past & Future Obligations towards Alter Pharma Group Waived
Past & Future Obligations towards Alter Pharma Group Waived Products Terms Results • €5.25M one-time lump sum • Acquires all royalty rights for • Maxigesic® IV Maxigesic IV (partnered with AFT) payment • HY-075 • Assumes sole responsibility for HY- • Potential €500K future earn-out 075 and HY-038; f
Slide 12: Additional Achievements Year-to-Date
Additional Achievements Year-to-Date R&D and Regulatory • Phase 1 start HY-004, an oral solution for use in specific dental procedures • Marketing application filed in U.S. for Tranexamic Acid RTU – discussions ongoing to address questions raised by FDA Corporate • Strengthened the organisation with
Slide 13: Financial Highlights: Period Ending 30 June 2021
Financial Highlights: Period Ending 30 June 2021 (in € thousand) HY 2021 HY 2020 % change Key Factors Revenue and other income 1,145 102 1,023% • Revenues: growth mainly driven by Maxigesic IV recognised income from Revenues 838 82 922% milestones Other income 307 20 1,435% • Operating expenses: imp
Slide 14: Core Assets: Anticipated Value Inflection Milestones in 2021
Core Assets: Anticipated Value Inflection Milestones in 2021 Clinical Regulatory Commercial • Atomoxetine: start + results • Maxigesic IV: marketing • Commercial partnership(s) pivotal study application in U.S. • In-licensing agreement(s) • HY-004: results Phase 1 and • Out-licensing agreement(s) pr
Slide 15: Q&A
Q&A \ 14
Slide 16: Contact us: investorrelations@hyloris.com
Contact us: investorrelations@hyloris.com
Hyloris Pharmaceuticals — H1 2021 Earnings Presentation on 6ix